Magnetocardiography (MCG) Device Use in Patients With Elevated Troponin

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06620744

Acronym

DUET

Enrollment

Registered

2024-10-01

Start date

2024-09-21

Completion date

2025-04-15

Last updated

2025-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ACS - Acute Coronary Syndrome

Keywords

magnetocardiography, MCG

Brief summary

This prospective device study will examine the feasibility of MCG data collection in a hospital setting using the SandboxAQ MCG device as a potential method to more accurately and quickly quantify cardiac disease of patients with elevated Troponin.

Interventions

DEVICESponsor MCG deivce

Unshielded device measuring cardiac magnetic fields.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Received a positive hs-cTnI based on the institutions laboratory normal value ranges (e.g. female ≥14 and male ≥35)

Exclusion criteria

* Present STEMI * Having an active atrial fibrillation episode as seen on 12-lead ECG * Clear non-ischemic cause for symptoms (e.g. trauma) * Active thoracic metal implants

Design outcomes

Primary

Measure	Time frame	Description
Proportion (%) of all collected MCG data that meets the necessary data quality. requirements and are deemed suitable for analysis.	Per-scan, on average 5 minutes, day of enrollment	MCG Data Quality

Secondary

Measure	Time frame	Description
Sandbox MCG safety	30-days	Device-related adverse events

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026